These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8396592)

  • 1. Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
    Fuchs PC; Barry AL; Pfaller MA
    J Clin Microbiol; 1993 Aug; 31(8):2236-7. PubMed ID: 8396592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.
    Jones RN; Erwin ME; Barrett MS
    Diagn Microbiol Infect Dis; 1992; 15(4):379-81. PubMed ID: 1319303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temafloxacin disk potency and tentative interpretive criteria for susceptibility tests.
    Barry AL; Jones RN
    J Clin Microbiol; 1989 Dec; 27(12):2861-3. PubMed ID: 2592548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-center validation of proposed disk diffusion susceptibility testing interpretive criteria for lomefloxacin using more than 1,500 clinical isolates.
    Cormican MG; Erwin MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Mar; 24(3):169-72. PubMed ID: 8724404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.
    Cormican MG; Jones RN
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):227-30. PubMed ID: 7554807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.
    Jones RN; Johnson DM; Erwin ME
    Diagn Microbiol Infect Dis; 1994 Feb; 18(2):125-7. PubMed ID: 8062531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
    Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T
    Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.
    Barry AL; Fuchs PC; Citron DM; Allen SD; Wexler HM
    J Antimicrob Chemother; 1993 Jun; 31(6):893-900. PubMed ID: 8395494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.
    Erwin ME; Jones RN
    J Clin Microbiol; 1992 May; 30(5):1170-3. PubMed ID: 1316366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.
    Barry AL; Fuchs PC; Allen SD; Jorgensen JH; Tenover FC; Murray PR; Hardy DJ; Baker CN
    J Clin Microbiol; 1993 Sep; 31(9):2375-80. PubMed ID: 8408559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
    Jones RN; Johnson DM
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):209-13. PubMed ID: 7554803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones.
    Fuchs PC; Barry AL; Brown SD
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):23-7. PubMed ID: 8950525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
    Sutton LD; Jones RN
    J Clin Microbiol; 1995 Jan; 33(1):146-8. PubMed ID: 7699031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)).
    Sewell DL; Barry AL; Allen SD; Fuchs PC; Murray PR; Tenover FC
    J Antimicrob Chemother; 1996 Jan; 37(1):139-43. PubMed ID: 8647755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
    Kayser FH; Wüst J
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):163-6. PubMed ID: 2060516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species.
    Kronvall G; Holst E
    Clin Microbiol Infect; 2000 Apr; 6(4):195-201. PubMed ID: 11168107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.
    Jones RN; Barrett MS; Biedenbach DJ
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):93-9. PubMed ID: 7805362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.